Clinical Data Shows Surefire Technology Achieved 79% Objective Response versus 37% Using a Standard Microcatheter in Treating Primary Liver Cancer
08. März 2017 06:00 ET
|
Surefire Medical, Inc.
Study presented at SIR 2017 Annual Scientific Meeting WASHINGTON, March 08, 2017 (GLOBE NEWSWIRE) -- Surefire Medical, Inc. today announced that clinical data presented at the Society for...